# Chenodal (chenodal) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/chenodal

> Chenodal (chenodal), sponsored by Mirum Pharmaceuticals, Inc. (MIRM): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Chenodal (chenodal) |
| Codes |  |
| Sponsor | Mirum Pharmaceuticals, Inc. (MIRM) https://sec-api.dev/companies/mirm/catalysts |
| Indications | [ctx, known](https://sec-api.dev/indications/ctx-known) |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Oct 2023: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0001759425-24-000038): "In October 2023, we reported positive topline data from our RESTORE clinical trial evaluating Chenodal in patients with CTX and we submitted a new drug application ("NDA") for chenodiol for the treatment of CTX to the FDA in June 2024, which application has been assigned a Prescription Drug User Fee Act ("PDUFA") date of December 28, 2024." https://www.sec.gov/Archives/edgar/data/1759425/000175942524000038/mirm-20240930.htm

### Oct 2023: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0001759425-24-000038): "In October 2023, we reported positive topline data from our RESTORE clinical trial evaluating Chenodal in patients with CTX and we submitted a new drug application ("NDA") for chenodiol for the treatment of CTX to the FDA in June 2024, which application has been assigned a Prescription Drug User Fee Act ("PDUFA") date of December 28, 2024." https://www.sec.gov/Archives/edgar/data/1759425/000175942524000038/mirm-20240930.htm

### Jun 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month. Stage: 3. Indication: CTX, known.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0001759425-24-000038): "We announced topline results of a Phase 3 clinical trial to evaluate the effects of Chenodal in patients with CTX, known as the RESTORE clinical trial, which we used to support our NDA submission in June 2024 for marketing authorization of Chenodal for CTX in the U.S. The FDA has accepted the NDA submission and has assigned a PDUFA date of December 28, 2024." https://www.sec.gov/Archives/edgar/data/1759425/000175942524000038/mirm-20240930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/chenodal.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chenodal (chenodal) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/chenodal

```bibtex
@misc{secapidev_pdufa_chenodal_20261116,
  title        = {Chenodal (chenodal) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/chenodal}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_chenodal_20261116","title":"Chenodal (chenodal) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/chenodal","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
